Page 2 - Gregory Vidal News Today

Experts on HR+/HER2- breast cancer review recent real-world data on CDK4/6 inhibitors and share excitement about first-line trials that have not yet read out.

Gregory Vidal, MD, PhD, presents ASCO 2023 data from the SONIA trial, which assessed the efficacy of CDK4/6 inhibitors when given as part of a combination with endocrine therapy (ET) in either the first- or second-line setting.

A comprehensive discussion on approaches to optimizing treatment selection and dosing in HR+/HER2- breast cancer.

Experts on HR+/HER2- breast cancer review data updates on adjuvant therapies from the 2023 ASCO Annual Meeting.

/PRNewswire/ -- At the 2023 ASCO annual meeting, investigators from OneOncologys clinical team will present Oral Abstracts using real-world data to evidence...

On this episode of Managed Care Cast, we feature several leaders in diversity, equity, and inclusion advancing health equity in their respective organization’s policy and practice initiatives.

Gregory Vidal, MD, PhD, explains why clinical trials need to be more representative of the whole breast cancer population, in order to account for differences in biology and social determinants.

Gregory Vidal, MD, PhD, discusses the unmet needs associated with racial disparities in patients with breast cancer.

/PRNewswire/ -- OneOncology, the platform for independent community oncology practices, announced the formation of five OneOncology Disease Groups. Each...

BARTLETT, Tenn. — Karen Boyd says her daughter Allison Robertson was "born to save my life."